Market Indices
Sector Heatmap
AYTU — AYTU BioPharma, Inc. Common Stock
NasdaqAYTU BioPharma, Inc. Common Stock
- O
- 2.08
- H
- 2.15
- L
- 2.06
- V
- 15.8K
AYTU — Latest News & Headlines
11 StoriesA depression drug generated $3.9 million in its first full quarter - Stock Titan
A depression drug generated $3.9 million in its first full quarter Stock Titan
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates Yahoo Finance
Aytu BioPharma Reports $16.1 Million Q4 Revenue as EXXUA Reaches $3.9 Million - Quiver Quantitative
Aytu BioPharma Reports $16.1 Million Q4 Revenue as EXXUA Reaches $3.9 Million Quiver Quantitative
AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary - TradingView
AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary TradingView
EXXUA prescriptions jump as Aytu BioPharma (AYTU) posts Q4 and full-year results - Stock Titan
EXXUA prescriptions jump as Aytu BioPharma (AYTU) posts Q4 and full-year results Stock Titan
Aytu BioScience Earnings Call Highlights EXXUA Momentum - The Globe and Mail
Aytu BioScience Earnings Call Highlights EXXUA Momentum The Globe and Mail
Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday Benzinga
Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4% - Investing.com UK
Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4% Investing.com UK
Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target - TradingView
Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target TradingView
Aytu BioPharma Q4FY26 Results: Sales up 6.4% YoY to $16.1M - scanx.trade
Aytu BioPharma Q4FY26 Results: Sales up 6.4% YoY to $16.1M scanx.trade
Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast By Investing.com - Investing.com Canada
Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast By Investing.com Investing.com Canada